Caris Life Sciences® (NASDAQ: CAI), a leading patient-centric next-generation AI TechBio company and precision medicine ...

Researchers at Oregon State University have developed an experimental strategy that could improve treatment for glioblastoma, the deadliest form of brain cancer. Credit: Parinaz Ghanbari A ...

NeoGenomics launched PTEN IHC CDx, the first IHC companion diagnostic test approved by the U.S. FDA for patients with ...

For women with invasive lobular carcinoma, pathogenic variants in breast cancer risk genes predict high odds of early recurrence.

2 Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA 3 The Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, ...

Men diagnosed with metastatic prostate cancer that lacks the PTEN protein now have a targeted drug option for the first time.

Men diagnosed with metastatic hormone-sensitive prostate cancer who carry a specific tumor deficiency now have a targeted ...

Capivasertib plus abiraterone/prednisone improved radiographic PFS in PTEN-deficient mAPMN/S prostate cancer (CAPItello-281) and launched with a VENTANA PTEN ...

The class of drugs known as DNA Damage Response inhibitors, which work by blocking cancer cells’ ability to repair their own damaged DNA, is expanding rapidly beyond its original anchor, the PARP ...

The first-in-class AKT inhibitor combination significantly reduced the risk of radiographic disease progression or death by 19% in an aggressive prostate cancer subtype. The Food and Drug ...

The FDA has cleared several oncology products over the past few days, ranging from therapies to diagnostic and imaging tools.

AstraZeneca’s TRUQAP® (capivasertib) in combination with abiraterone and prednisone has been approved in the US as the first and only targeted treatment for adult patients with PTEN-deficient ...